NCT07340723 (GVHD) is a Phase 2 clinical trial of Ruxolitinib in GVHD,Acute, sponsored by Daihong Liu.

Who is sponsoring NCT07340723?

NCT07340723 is sponsored by Daihong Liu.

What drugs are being tested in NCT07340723?

Interventions in NCT07340723: Ruxolitinib, Corticosteroids.

What condition does NCT07340723 study?

NCT07340723 studies GVHD,Acute, Stem Cell Transplant Complications.

Is NCT07340723 still recruiting?

NCT07340723 is currently recruiting now. Last updated 14 January 2026.

Last reviewed 2026-01-14 · How we verify

NCT07340723: GVHD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )

Recruiting now Phase 2 Last updated 14 January 2026

What this trial tests

Phase 2 trial testing Ruxolitinib in GVHD,Acute in 168 participants. Currently enrolling.

Timeline

1 June 2025

Primary endpoint
1 June 2027

1 June 2027

Quick facts

Lead sponsor	Daihong Liu
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	168
Start date	1 June 2025
Primary completion	1 June 2027
Estimated completion	1 June 2027
Sites	1 location across China

Drugs / interventions tested

Ruxolitinib (RUXOLITINIB) — full drug profile →
Corticosteroids (corticosteroids) — full drug profile →

Conditions studied

GVHD,Acute — all drugs for GVHD,Acute →
Stem Cell Transplant Complications — all drugs for Stem Cell Transplant Complications →

Sponsor

Daihong Liu — full company profile →

Who can join

14 and older, any sex, with GVHD,Acute or Stem Cell Transplant Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for grade II acute GVHD (graft-versus-host disease )

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ruxolitinib

Trials testing the same drug.

NCT07498205 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts · Phase 4 · not yet recruiting
NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
NCT07311746 — Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07340138 — Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis · Phase 1 · not yet recruiting
NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting

Other recruiting trials for GVHD,Acute

Currently open trials in the same condition.

NCT06462365 — Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) · Phase 1 · recruiting
NCT05718791 — CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease · recruiting

Other Daihong Liu trials

Trials by the same sponsor.

NCT07489534 — Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction · Phase 2 · recruiting
NCT07321301 — Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia · Phase 2 · recruiting
NCT07509749 — Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease) · Phase 2 · recruiting
NCT07450391 — EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders · Phase 1, PHASE2 · recruiting
NCT07094464 — Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07340723 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daihong Liu
Last refreshed: 14 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07340723.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing